Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 June 2023 | Story André Damons | Photo Supplied
Prof Champion Nyoni and Prof Motlalepula Matsabisa
Prof Champion Nyoni, Senior Researcher in the School of Nursing at the University of the Free State (UFS). Prof Motlalepula Matsabisa, an African traditional medicine expert and Head of the African Medicines Innovations and Technologies Development Platform (AMITD) within the UFS Department of Pharmacology.

Prof Champion Nyoni, Senior Researcher in the School of Nursing at the University of the Free State (UFS), has been appointed to the World Health Organisation (WHO) Academy Standing Advisory Quality Committee – making him the only representative from Africa to serve in this academy.

Another UFS staff member, Prof Motlalepula Matsabisa, an expert on African traditional medicine and Head of the African Medicines Innovations and Technologies Development Platform (AMITD) within the Department of Pharmacology, has also been appointed to serve on a WHO initiative – the WHO Global Centre for Traditional Medicine Editorial Board/Evidence Task Force. His appointment will be effective until the end of December 2023.

Prof Matsabisa will also attend the first WHO Traditional Medicine Global Summit in India in August 2023, after being invited to serve as a member of the Summit External Advisory Group for the WHO Traditional Medicine Global Summit (‘Advisory Group’).

The appointment of Prof Nyoni, who is the current Chairperson of the Board of Directors for the Africa Interprofessional Education Network (AfrIPEN), and Deputy Chair of the Board for Interprofessional.Global a global confederation of interprofessional networks based in the Netherlands – will be effective for two years.

The WHO Academy is a priority initiative of the WHO transformation agenda and will support accelerated learning and skills recognition of staff and external stakeholders to advance the implementation of the WHO's strategic plan and ‘triple billion’ goal: ensuring that by 2023, an additional one billion people benefit from universal health coverage; one billion more are afforded better protection in health emergencies, and one billion more enjoy improved health and well-being.

Work and contribution being recognised

“I feel thrilled about this exciting adventure. I think this is an exciting opportunity in my career to be recognised by an organisation such as the WHO to serve in the capacity of adviser. I think this is a huge feather in my cap, our School of Nursing, and the faculty. My work and contribution are being recognised and this is a good thing. I am hoping to make an impact in this committee and to also learn from it,” says Prof Nyoni.

Even though there is a bit of pressure representing the whole continent, Prof Nyoni believes his experience with global organisations will come in handy. He is ready to take on the challenge, give it his best, and leave a legacy of excellence.

“Due to the complexity of health professions education in our context, our different cultural, geographical, and socio-economic issues, it is truly an interesting concept to actually think of representing an entire region. I have worked in and continue to work in many countries in Africa through various research projects and postgraduate students, which gives one some insight into what is happening in the region, but often one needs to know more.”

Global knowledge centre for traditional medicine

For Prof Matsabisa, who is also the chairperson of the WHO Regional Expert Advisory Committee on Traditional Medicine (REACT), it is always thrilling to be recognised by serving in such world bodies.

The WHO Global Centre for Traditional Medicine (WHO-GCTM) was established in 2022 as a global knowledge centre for traditional medicine to harness the potential of traditional medicine from across the world through modern science and technology in order to improve the health of people and the planet.

“I look at myself most of the time and ask myself what I am doing right to be given such recognition globally. I am, however, always ready and prepared to take such responsibilities and challenges. I feel happy and great knowing that my expertise and experience is recognised so far from home. I will do my best and try not to fail anyone. I will give it my all and put my whole heart into this task,” says Prof Matsabisa.

He looks forward to seeing the WHO develop tools and guidelines that will promote the institutionalisation of traditional medicine and to come up with positive resolutions on how to take traditional medicines forward.

World takes traditional medicine seriously

According to Prof Matsabisa, the world is now taking traditional medicines seriously. The developed world is now serious about using traditional medicines for their daily health needs and consumption. The world is accepting the positive and important role that traditional medicine is playing in our health-care needs and how it is contributing to the health and well-being of people.

“It is unfortunate that, at home, we have sceptics and people still living in the past who are blind to the importance of traditional medicines. The WHO is now seriously taking the lead in giving advice and guidelines on traditional medicines. It makes me very happy to see these significant movements around traditional medicines."

Africa, Prof Matsabisa concludes, still has its natural resources and its indigenous knowledge as the main remaining tools to get the continent into development and economic freedom. If strategic decisions could be made around developments based on the natural resources for local beneficiation and moving away from the ‘thinking about resources’ to a knowledge-based economy, we could take the continent out of poverty, famine, and wars, and redirect resources to development, technical skills development, and wealth generation for all.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept